Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells

Blood

Volumn 125, Issue 22, 2015, Pages 3447-3454

  Hajj, Hiba El ^a   Dassouki, Zeina ^a   Berthier, Caroline ^b   Raffoux, Emmanuel ^c   Ades, Lionel ^c,d   Legrand, Olivier ^e,f   Hleihel, Rita ^a   Sahin, Umut ^b   Tawil, Nadim ^a   Salameh, Ala ^a   Zibara, Kazem ^g   Darwiche, Nadine ^a   Mohty, Mohamad ^e,f   Dombret, Hervé ^c   Fenaux, Pierre ^c,d   De Thé, Hugues ^b,c   Bazarbachi, Ali ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b l'alimentation et l'Environnement   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d AVICENNE HOSPITAL   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g LEBANESE UNIVERSITY   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; NUCLEOPHOSMIN; RETINOIC ACID; MUTANT PROTEIN; NUCLEAR PROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL LINE; CLINICAL ARTICLE; DRUG POTENTIATION; GENE; GENE MUTATION; HUMAN; HUMAN CELL; NUCLEOLUS; NUCLEOPHOSMIN GENE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; AGED; CELL DIFFERENTIATION; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL CULTURE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; APOPTOSIS; ARSENICALS; CELL DIFFERENTIATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTANT PROTEINS; MUTATION; NUCLEAR PROTEINS; OXIDES; PROTEOLYSIS; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 84930966152     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-11-612416     Document Type: Article

References (36)

1. Ferrara F. Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia? Hematol Oncol. 2014; 32(1):1-9.
2. Grimwade D, Hills RK, Moorman AV, et al; National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
3. Fröhling S, Schlenk RF, Breitruck J, et al; AML Study Group Ulm. Acute myeloid leukemia. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100(13):4372-4380.
4. Grisendi S, Bernardi R, Rossi M, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature. 2005;437(7055):147-153.
5. Falini B, Bolli N, Liso A, et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia. 2009;23(10): 1731-1743.
6. Cheng K, Sportoletti P, Ito K, et al. The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model. Blood. 2010;115(16):3341-3345.
7. Chou SH, Ko BS, Chiou JS, et al. A knock-in Npm1 mutation in mice results in myeloproliferation and implies a perturbation in hematopoietic microenvironment. PLoS ONE. 2012;7(11):e49769.
8. Mallardo M, Caronno A, Pruneri G, et al. NPMc1 and FLT3-ITD mutations cooperate in inducing acute leukaemia in a novel mouse model. Leukemia. 2013;27(11):2248-2251.
9. Mupo A, Celani L, Dovey O, et al. A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. Leukemia. 2013;27(9): 1917-1920.
10. Shlush LI, Zandi S, Mitchell A, et al; HALT Pan-Leukemia Gene Panel Consortium. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506(7488): 328-333.
11. Vassiliou GS, Cooper JL, Rad R, et al. Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nat Genet. 2011;43(5):470-475.
12. Schlenk RF, Döhner K, Kneba M, et al; German-Austrian AML Study Group (AMLSG). Gene mutations and response to treatment with alltrans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica. 2009;94(1): 54-60.
13. Burnett AK, Hills RK, Green C, et al. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood. 2010;115(5): 948-956.
14. Nazha A, Bueso-Ramos C, Estey E, et al. The addition of all-trans retinoic acid to chemotherapy may not improve the outcome of patient with NPM1 mutated acute myeloid leukemia. Front Oncol. 2013;3:218.
15. Dos Santos GA, Kats L, Pandolfi PP. Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med. 2013; 210(13):2793-2802.
16. de Th é H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010;10(11): 775-783.
17. Ablain J, Rice K, Soilihi H, de Reynies A, Minucci S, de Thé H. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nat Med. 2014; 20(2):167-174.
18. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med. 1999; 189(7):1043-1052.
19. Nasr R, Guillemin MC, Ferhi O, et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med. 2008; 14(12):1333-1342.
20. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009; 27(4):504-510.
21. Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2004;101(15):5328-5335.
22. Lo-Coco F, Avvisati G, Vignetti M, et al; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013; 369(2):111-121.
23. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440-446.
24. Efficace F, Mandelli F, Avvisati G, et al. Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-oflife outcomes. J Clin Oncol. 2014;32(30): 3406-3412.
25. Falini B, Mecucci C, Tiacci E, et al; GIMEMA Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005; 352(3):254-266.
26. Ivanschitz L, De Thé H, Le Bras M. PML, SUMOylation, and Senescence. Front Oncol. 2013;3:171.
27. Sahin U, Lallemand-Breitenbach V, de Thé H. PML nuclear bodies: regulation, function and therapeutic perspectives. J Pathol. 2014;234(3): 289-91.
28. Sahin U, Ferhi O, Jeanne M, et al. Oxidative stress-induced assembly of PML nuclear bodies controls sumoylation of partner proteins. J Cell Biol. 2014;204(6):931-945.
29. Lehmann-Che J, Bally C, de Thé H. Resistance to therapy in acute promyelocytic leukemia. N Engl J Med. 2014;371(12):1170-1172.
30. Ablain J, Leiva M, Peres L, Fonsart J, Anthony E, de Thé H. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies. J Exp Med. 2013; 210(4):647-653.
31. Vitaliano-Prunier A, Halftermeyer J, Ablain J, et al. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation. Blood. 2014; 124(25):3772-3780.
32. Balusu R, Fiskus W, Rao R, et al. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood. 2011;118(11): 3096-3106.
33. Lallemand-Breitenbach V, de Thé H. PML nuclear bodies. Cold Spring Harb Perspect Biol. 2010; 2(5):a000661.
34. Haindl M, Harasim T, Eick D, Muller S. The nucleolar SUMO-specific protease SENP3 reverses SUMO modification of nucleophosmin and is required for rRNA processing. EMBO Rep. 2008;9(3):273-279.
35. Lindstrom MS. NPM1/B23: A multifunctional chaperone in ribosome biogenesis and chromatin remodeling. Biochem Res Int. 2011;2011:195209.
36. Huang M, Thomas D, Li MX, et al. Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib. Leukemia. 2013; 27(10):1970-1980.